EP4220176A3 - Biomarqueurs - Google Patents

Biomarqueurs Download PDF

Info

Publication number
EP4220176A3
EP4220176A3 EP23164742.1A EP23164742A EP4220176A3 EP 4220176 A3 EP4220176 A3 EP 4220176A3 EP 23164742 A EP23164742 A EP 23164742A EP 4220176 A3 EP4220176 A3 EP 4220176A3
Authority
EP
European Patent Office
Prior art keywords
osteoarthritis pain
biomarkers
methods
diagnosis
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23164742.1A
Other languages
German (de)
English (en)
Other versions
EP4220176A2 (fr
Inventor
Nidhi SOFAT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Georges Hospital Medical School
Original Assignee
St Georges Hospital Medical School
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Georges Hospital Medical School filed Critical St Georges Hospital Medical School
Publication of EP4220176A2 publication Critical patent/EP4220176A2/fr
Publication of EP4220176A3 publication Critical patent/EP4220176A3/fr
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP23164742.1A 2017-02-27 2018-02-27 Biomarqueurs Pending EP4220176A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1703123.8A GB201703123D0 (en) 2017-02-27 2017-02-27 Biomarkers
PCT/GB2018/050502 WO2018154337A1 (fr) 2017-02-27 2018-02-27 Biomarqueurs
EP18712262.7A EP3586144B1 (fr) 2017-02-27 2018-02-27 Biomarqueurs

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP18712262.7A Division EP3586144B1 (fr) 2017-02-27 2018-02-27 Biomarqueurs
EP18712262.7A Division-Into EP3586144B1 (fr) 2017-02-27 2018-02-27 Biomarqueurs

Publications (2)

Publication Number Publication Date
EP4220176A2 EP4220176A2 (fr) 2023-08-02
EP4220176A3 true EP4220176A3 (fr) 2023-10-18

Family

ID=58544099

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18712262.7A Active EP3586144B1 (fr) 2017-02-27 2018-02-27 Biomarqueurs
EP23164742.1A Pending EP4220176A3 (fr) 2017-02-27 2018-02-27 Biomarqueurs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18712262.7A Active EP3586144B1 (fr) 2017-02-27 2018-02-27 Biomarqueurs

Country Status (4)

Country Link
EP (2) EP3586144B1 (fr)
JP (2) JP7116073B2 (fr)
GB (1) GB201703123D0 (fr)
WO (1) WO2018154337A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3911411A4 (fr) * 2019-01-14 2023-04-12 President and Fellows of Harvard College Procédés et compositions pour restaurer les taux de stmn2
CN111808938A (zh) * 2019-04-11 2020-10-23 南方医科大学南方医院 Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
WO2021041324A2 (fr) * 2019-08-23 2021-03-04 Duke University Compositions et procédés pour le traitement de douleurs et de démangeaisons pathologiques

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (fr) * 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba et ses derives utilises pour le traitement de la douleur
US20070292881A1 (en) * 2006-05-25 2007-12-20 Eleanor Fish Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis
WO2015136298A1 (fr) * 2014-03-13 2015-09-17 Isis Innovation Limited Procédés et système de détermination de la présence d'une maladie chez un sujet
US20150258094A1 (en) * 2014-03-14 2015-09-17 Rhode Island Hospital Nanocarriers And Their Processing For Diagnostics And Therapeutics
WO2016127035A1 (fr) * 2015-02-05 2016-08-11 Duke University Procédés de détection de l'arthrose et de prédiction de son évolution

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003167A1 (fr) * 1996-07-24 1998-01-29 Warner-Lambert Company Isobutylgaba et ses derives utilises pour le traitement de la douleur
US20070292881A1 (en) * 2006-05-25 2007-12-20 Eleanor Fish Methods of diagnosing and treating rheumatoid arthritis and osteoarthritis
WO2015136298A1 (fr) * 2014-03-13 2015-09-17 Isis Innovation Limited Procédés et système de détermination de la présence d'une maladie chez un sujet
US20150258094A1 (en) * 2014-03-14 2015-09-17 Rhode Island Hospital Nanocarriers And Their Processing For Diagnostics And Therapeutics
WO2016127035A1 (fr) * 2015-02-05 2016-08-11 Duke University Procédés de détection de l'arthrose et de prédiction de son évolution

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JESÚS MATEOS ET AL: "Differential protein profiling of synovial fluid from rheumatoid arthritis and osteoarthritis patients using LC MALDI TOF/TOF", JOURNAL OF PROTEOMICS, vol. 75, no. 10, 8 January 2012 (2012-01-08), pages 2869 - 2878, XP028507158, ISSN: 1874-3919, [retrieved on 20120108], DOI: 10.1016/J.JPROT.2011.12.042 *
MENG ET AL: "Microarray analysis of differential gene expression in temporomandibular joint condylar cartilage after experimentally induced osteoarthritis", OSTEOARTHRITIS AND CARTILAGE, ELSEVIER, AMSTERDAM, NL, vol. 13, no. 12, 1 December 2005 (2005-12-01), pages 1115 - 1125, XP005177310, ISSN: 1063-4584, DOI: 10.1016/J.JOCA.2005.03.010 *
OLEX AMY L ET AL: "Integration of gene expression data with network-based analysis to identify signaling and metabolic pathways regulated during the development of osteoarthritis", GENE, ELSEVIER AMSTERDAM, NL, vol. 542, no. 1, 12 March 2014 (2014-03-12), pages 38 - 45, XP028844381, ISSN: 0378-1119, DOI: 10.1016/J.GENE.2014.03.022 *

Also Published As

Publication number Publication date
EP4220176A2 (fr) 2023-08-02
JP2022160535A (ja) 2022-10-19
EP3586144B1 (fr) 2023-06-07
GB201703123D0 (en) 2017-04-12
JP2020510423A (ja) 2020-04-09
WO2018154337A1 (fr) 2018-08-30
EP3586144A1 (fr) 2020-01-01
JP7116073B2 (ja) 2022-08-09

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
WO2018081648A8 (fr) Anticorps anti-mic et méthodes d'utilisation
MY193661A (en) Anti-tim3 antibodies and methods of use
CR20230163A (es) ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271)
MX2017000419A (es) Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
WO2018106776A3 (fr) Anticorps anti-tau et méthodes d'utilisation de ces derniers
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2019011423A (es) Metodos de tratamiento de enfermedades neurodegenerativas.
AU2016328995B2 (en) Molybdenum disulfide and related materials for water treatment
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
EP3427051A4 (fr) Biomarqueurs protéiques et d'auto-anticorps pour le diagnostic et le traitement du cancer du poumon
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
MX2022003212A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecificos anti-klk5/klk7 y metodos de uso.
EP4220176A3 (fr) Biomarqueurs
EP3693742A3 (fr) Procédés pour détecter le cancer de la prostate
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX2020008408A (es) Imagenologia y terapia dirigidas por la granzima b.
EA201592265A1 (ru) Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof
MX2016015280A (es) Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3586144

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20230913BHEP

Ipc: G01N 33/68 20060101AFI20230913BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240405

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR